madman
Super Moderator
Key issues
• The use of testosterone therapy (TTh) for late onset hypogonadism has been questioned due to possible increased cardiovascular risk.
• Food and Drug Administration Drug Administration (FDA) in its final release approved TTh only for men with “classical hypogonadism”, i.e. due to primary or secondary T deficiency resulting from known problems within the testis, pituitary, or hypothalamus (e.g. genetic problems, or damage from surgery, chemotherapy, or infection).
• Available data on TTh derived from randomized clinical trials published in the last 7 years suggest that CV risk is not a major issue.
• Possible advantages in CV prevention can be detected in specific subpopulations (i.e obese men without major comorbidities).
• Duration of the available trials is short (lower that 3 years). Hence, limited information on possible long-term effects of TTh on CV
• The use of testosterone therapy (TTh) for late onset hypogonadism has been questioned due to possible increased cardiovascular risk.
• Food and Drug Administration Drug Administration (FDA) in its final release approved TTh only for men with “classical hypogonadism”, i.e. due to primary or secondary T deficiency resulting from known problems within the testis, pituitary, or hypothalamus (e.g. genetic problems, or damage from surgery, chemotherapy, or infection).
• Available data on TTh derived from randomized clinical trials published in the last 7 years suggest that CV risk is not a major issue.
• Possible advantages in CV prevention can be detected in specific subpopulations (i.e obese men without major comorbidities).
• Duration of the available trials is short (lower that 3 years). Hence, limited information on possible long-term effects of TTh on CV
